When you choose KANJINTI®

AMGEN OFFERS PERSONALIZED SUPPORT FOR YOUR PATIENTS

KANJINTI® (trastuzumab-anns) For Injection

KANJINTI® is indicated for the treatment of:2

  • HER2-overexpressing breast cancer
  • HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
KANJINTI® SETS A RIGOROUS STANDARD
FOR HERCEPTIN® BIOSIMILARITY
The first and only Herceptin® biosimilar with single-transition study data in the eBC setting

FDA approved with highly similar safety and efficacy to Herceptin®, with no clinically meaningful differences.2,3

btn-medi_rainbow-svgtotality of evidence
Comprehensive support for you and your patients

Comprehensive support for you and your patients

btn-medi_rainbow-svgsupport
same support

Amgen has an incredible track record of reliable supply.4

btn-medi_rainbow-svgbiosimilar expertise

Backed by
Amgen Expertise

40+

Years

experience in biologics

btn-medi_rainbow-svgbiosimilar expertise

HER2 = human epidermal growth factor receptor 2; IV = intravenous.

AMGEN® Biosimilars

Get the story behind Amgen's
commitment to biosimilars.

Amgen Biosimilars
×
Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.